Drug Profile
Plozasiran - Arrowhead Pharmaceuticals
Alternative Names: ARO-APOC3Latest Information Update: 11 Apr 2024
Price :
$50
*
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Antihyperlipidaemics; Small interfering RNA
- Mechanism of Action Apolipoprotein C-III inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hyperlipoproteinaemia type I
- Phase II Dyslipidaemias; Hypertriglyceridaemia
Most Recent Events
- 07 Apr 2024 Final efficacy and adverse events data from the phase II SHASTA-2 trial in Hypertriglyceridaemia released by Arrowhead Pharmaceuticals
- 04 Apr 2024 Arrowhead Pharmaceuticals plans phase III trial MUIR-3 in Hypertriglyceridemia in May 2024 (SC, Injection) (NCT06347133) (EudraCT2023-509302-30)
- 04 Apr 2024 Arrowhead Pharmaceuticals plans phase III trial SHASTA-3 in Hypertriglyceridemia in May 2024 (SC, Injection) (NCT06347003)